Q32 BIO INC (QTTB) Stock Price, Forecast & Analysis
USA - NASDAQ:QTTB - US7469641051 - Common Stock
QTTB Key Statistics, Chart & Performance
The current stock price of QTTB is 2.26 USD. In the past month the price decreased by -36.69%. In the past year, price decreased by -95.01%.
QTTB Latest News, Press Relases and Analysis
QTTB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About QTTB
Company Profile
Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts and currently employs 27 full-time employees. The company went IPO on 2018-03-28. The company focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). The company has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.
Company Info
Q32 BIO INC
830 Winter Street
Waltham MASSACHUSETTS US
Employees: 27
Phone: 17819990232
Q32 BIO INC / QTTB FAQ
Can you describe the business of Q32 BIO INC?
Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts and currently employs 27 full-time employees. The company went IPO on 2018-03-28. The company focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). The company has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.
What is the stock price of Q32 BIO INC today?
The current stock price of QTTB is 2.26 USD. The price decreased by -2.59% in the last trading session.
Does Q32 BIO INC pay dividends?
QTTB does not pay a dividend.
How is the ChartMill rating for Q32 BIO INC?
QTTB has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for QTTB stock?
Q32 BIO INC (QTTB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.3).
What is the market capitalization of QTTB stock?
Q32 BIO INC (QTTB) has a market capitalization of 27.57M USD. This makes QTTB a Nano Cap stock.
When does Q32 BIO INC (QTTB) report earnings?
Q32 BIO INC (QTTB) will report earnings on 2026-05-06.
QTTB Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to QTTB. When comparing the yearly performance of all stocks, QTTB is a bad performer in the overall market: 90.02% of all stocks are doing better.
QTTB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to QTTB. Both the profitability and financial health of QTTB have multiple concerns.
QTTB Financial Highlights
Over the last trailing twelve months QTTB reported a non-GAAP Earnings per Share(EPS) of -4.3. The EPS increased by 86.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -75.58% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
QTTB Forecast & Estimates
9 analysts have analysed QTTB and the average price target is 10.2 USD. This implies a price increase of 351.33% is expected in the next year compared to the current price of 2.26.